OLX 104C
Alternative Names: OLX-104CLatest Information Update: 05 Dec 2022
At a glance
- Originator OliX Pharmaceuticals
- Class Skin disorder therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alopecia
Highest Development Phases
- Preclinical Alopecia
Most Recent Events
- 22 Nov 2022 OliX Pharmaceuticals plans to submit a Human Research Ethics Application (HREA) for phase I trial for Alopecia by end of 2022
- 22 Nov 2022 Pharmacodynamics data from preclinical study in Alopecia released by OliX Pharmaceuticals
- 28 Dec 2021 OLX 104C is available for licensing in World as of 21 Oct 2021